Skip to Content
Merck
  • ATP13A2 modifies mitochondrial localization of overexpressed TOM20 to autolysosomal pathway.

ATP13A2 modifies mitochondrial localization of overexpressed TOM20 to autolysosomal pathway.

PloS one (2022-11-30)
Yuta Hatori, Yukina Kanda, Saori Nonaka, Hiroshi Nakanishi, Takeo Kitazawa
ABSTRACT

Mutations in ATP13A2 cause Kufor-Rakeb Syndrome (KRS), a juvenile form of Parkinson's Disease (PD). The gene product belongs to a diverse family of ion pumps and mediates polyamine influx from lysosomal lumen. While the biochemical and structural studies highlight its unique mechanics, how PD pathology is linked to ATP13A2 function remains unclear. Here we report that localization of overexpressed TOM20, a mitochondrial outer-membrane protein, is significantly altered upon ATP13A2 expression to partially merge with lysosome. Using Halo-fused version of ATP13A2, ATP13A2 was identified in lysosome and autophagosome. Upon ATP13A2 co-expression, overexpressed TOM20 was found not only in mitochondria but also within ATP13A2-containing autolysosome. This modification of TOM20 localization was inhibited by adding 1-methyl-4-phenylpyridinium (MPP+) and not accompanied with mitophagy induction. We suggest that ATP13A2 may participate in the control of overexpressed proteins targeted to mitochondrial outer-membrane.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ATP13A2 antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
ANTI-ATP13A3 (N-TERM) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution